The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
Kiyotaka Yoh(National Cancer Center Hospital East), Kōichi Goto(National Cancer Center Hospital East), Taku Nakagawa(Saint John's Health Center), Jun Sakakibara‐Konishi(Hokkaido University), Genichiro Ishii(Juntendo University), Yuichiro Hayashi(Keio University), Koichi Nishi(Ishikawa Prefectural Central Hospital), Kei Kunimasa(Kobe University), Masahiro Kodani(Tottori University), Shunichi Sugawara(Sendai Kousei Hospital), Tomohiro Kato(St. Marianna University School of Medicine), Shingo Matsumoto(National Cancer Center Hospital East), Koji Tsuta(Kansai Medical University), Noriko Motoi(Tokyo National Hospital)
Cited by 5
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835